Live Breaking News & Updates on ஆண்டு ஆஃப் முயற்சி

Stay updated with breaking news from ஆண்டு ஆஃப் முயற்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Worldwide Industry for Microbial Contract Biomanufacturing to 2030 - COVID-19 is Likely to Create Significant Business Opportunities


Share this article
Share this article
ResearchAndMarkets.com s offering.
The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. The study also features a detailed analysis of key drivers and trends related to this evolving domain.
Traditionally, microbial cell cultures have been the preferred choice for the production of the variety of biologics, including peptide therapeutics and certain low molecular weight proteins (insulin) and cytokines. Till date, over 60% of recombinant proteins used for therapeutic purposes, are estimated to be produced using microbial expression systems, primarily Escherichia coli. In fact, more than 70 biologics approved by various regulatory authorities, worldwide, are manufactured using microbial fermentation. It is worth highlighting that the growing interest in certain novel biologics, such as antibody fragments and plasmid DNA (w ....

United States , Luina Bio , Boehringer Ingelheim Bioxcellence , Altor Bioscience , Aumgene Biosciences , Akshaya Bio , Akers Biosciences , Asia Pacific , Porton Biopharma , Arranta Bio , Biosynergy Europe , Max Rossetto , Axcellerate Pharma , Bristol Myers Squibb , Northway Biotechpharma , Stelis Biopharma , Bcmos Cdmos , Bio Elpida , Gaurav Kaushik , Laura Wood , Purpose Of Initiative , Year Of Initiative , Affinity Life Sciences , Boehringer Ingelheim , Companies In Asia Pacific , Bexion Pharmaceuticals ,